Teriparatide
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Teriparatide and local guidelines before prescribing.
Anabolic bone agent
Mechanism
Recombinant parathyroid hormone fragment (anabolic).
Uses
Severe osteoporosis.
Dosing
- Teriparatide | 20 micrograms SC daily for up to 24 months. Very high risk and glucocorticoid-induced osteoporosis. Follow with an antiresorptive.
Endocrinology: Bone Medicine
Side effects
Nausea, leg cramps, dizziness, hypercalcaemia, injection-site reactions.
Interactions
Digoxin toxicity with hypercalcaemia.
Contraindications and cautions
Hypercalcaemia, Paget disease, previous radiotherapy to skeleton
Monitoring
Calcium
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Avoid in severe renal impairment
Overdose and reversal
Supportive
Special advice
Maximum 24 months; follow with antiresorptive.
More from the textbook: uses, cautions and other points
- Teriparatide (PTH analogue, daily injection, for up to 24 months) - builds bone; hypercalcaemia, dizziness; avoid in Paget's, previous skeletal radiotherapy, bone cancer.
Endocrine: Anatomy Physiology and Pharmacology - Teriparatide / romosozumab | Bone-building; romosozumab - avoid after MI or stroke.
Endocrine: Anatomy Physiology and Pharmacology - Treatment: Alendronate, risedronate, zoledronic acid, denosumab (licensed in men, including on androgen deprivation), or teriparatide. Testosterone replacement for hypogonadism, unless contraindicated.
Endocrinology: Bone Medicine - Teriparatide (daily SC — PTH 1–34) | Anabolic — intermittent PTH stimulates osteoblasts | Severe osteoporosis with vertebral fractures; maximum 2 years; then anti-resorptive; avoid with Paget's, prior radiotherapy, high calcium
Rheumatology Anatomy Physiology Pharmacology - Anabolic: Stimulate osteoblasts to build new bone - teriparatide, abaloparatide, romosozumab. These produce bigger, faster gains.
Endocrinology: Bone Medicine - Anabolic courses: Fixed duration (teriparatide 24 months, abaloparatide 18 months, romosozumab 12 months), always followed by antiresorptive treatment.
Endocrinology: Bone Medicine - Very high risk (e.g. multiple vertebral fractures): Consider teriparatide , which is superior to alendronate in glucocorticoid-induced osteoporosis.
Endocrinology: Bone Medicine - Specialist review - teriparatide or bisphosphonates may be considered after breastfeeding ends, with careful counselling about future pregnancy.
Endocrinology: Bone Medicine
Where it is discussed in the book
- Endocrine: Anatomy Physiology and Pharmacology (2 mentions)
- Endocrinology: Bone Medicine (7 mentions)
- Rheumatology Anatomy Physiology Pharmacology (3 mentions)
- Medicine of the older adult.: Falls, syncope, mobility and fragility fractures (2 mentions)